The ice pack test — a simple procedure in which a bag filled with ice is placed over the eyelids for a few minutes — eased ptosis (upper eyelid drooping) in a man with Lambert-Eaton myasthenic syndrome (LEMS), according to a recent case report. These findings suggest this test…
Catalyst Pharmaceuticals and KYE Pharmaceuticals have reached an exclusive agreement that will enable KYE to commercialize Firdapse (amifampridine), Catalyst’s oral therapy for adults with Lambert-Eaton myasthenic syndrome (LEMS), in Canada. The announcement comes after the medication was approved by Health Canada earlier this month.
A post-exercise facilitation test, which measures muscle activity following voluntary muscle contraction or electrical stimulation, can help identify the effects of carpal tunnel syndrome (CTS) on nerves and muscles in people with Lambert-Eaton myasthenic syndrome (LEMS), a case report shows. The study, “Use of Post-Exercise…
A new scoring tool can be used to effectively estimate the risk of developing small cell lung cancer (SCLC) for a person with Lambert-Eaton myasthenic syndrome (LEMS), according to a new study. Smoking, being age 50 or older, and significant weight loss within three months of LEMS onset all…
People with Lambert-Eaton myasthenia syndrome (LEMS) have a specific response pattern to repetitive nerve stimulation — known as RNS — that may enable physicians to easily distinguish such cases from the neuromuscular condition myasthenia gravis (MG), a study reports. The study, “Lambert-Eaton myasthenia syndrome:…
Despite the COVID-19 pandemic, Catalyst Pharmaceuticals is still expecting Firdapse (amifampridine) to be approved for the treatment of Lambert-Eaton myasthenic syndrome (LEMS) in Canada later this year, the company announced in an update. The company’s new drug submission (NDS) to Health Canada seeking approval…
A group of experts have provided a series of recommendations for people with myasthenia gravis (MG) and Lambert-Eaton myasthenic syndrome (LEMS) who rely on immunosuppressants to help manage their condition during the COVID-19 outbreak. Their guidelines, titled “Guidance for the management of myasthenia…
Patients with Lambert-Eaton myasthenic syndrome (LEMS) live as long as people who do not have the disease, and can lead a relatively normal life despite having some physical limitations, a study contends. The study, “Long‐term follow‐up, quality of life, and survival of patients with Lambert‐Eaton myasthenic syndrome,” was…
Treatment with Firdapse (Amifampridine phosphate) or Ruzurgi (3,4‐diaminopyridine, or 3,4‐DAP) is effective and well-tolerated among people with Lambert-Eaton myasthenic syndrome (LEMS), even in the presence of immunosuppressants or other medications that alter the responsiveness of the immune system, a review has found. The review study,…
3,4‐diaminopyridine — the active ingredient of the only FDA-approved treatment for adults with Lambert-Eaton myasthenic syndrome (LEMS) — effectively targets muscles in rats and has a long-lasting effect in the body, a study says. The findings of the study, “Pharmacokinetics and Tissue Distribution of 3,4‐Diaminopyridine in Rats,”…
Get regular updates to your inbox.